Categories
Health

AstraZeneca says gross sales rose 10% in 2020, sees income progress forward

A box of vials with the AstraZeneca Covid-19 vaccine is pictured on February 6, 2021 at Foch Hospital in Suresnes at the start of a vaccination campaign for health workers with the AstraZeneca / Oxford vaccine.

Alain Jocard | AFP | Getty Images

AstraZeneca announced on Thursday that product sales increased 10% in 2020. This year, the drug maker attracted attention for its work on developing a coronavirus vaccine.

The Anglo-Swedish pharmaceutical company reported total product sales of $ 25.8 billion for the year. In the fourth quarter, sales rose 12% to just over $ 7 billion. The company said it was the first time in “many years” that quarterly product sales were this strong. Total revenue for the year was $ 26.6 billion and the fourth quarter was $ 7.4 billion.

CEO Pascal Soriot said last year’s performance was “a significant step forward for AstraZeneca. Despite the significant impact of the pandemic, we achieved double-digit sales growth.”

“The consistent successes in the pipeline, the accelerated performance of our business and the advancement of the COVID-19 vaccine have shown what we can achieve,” he added in a statement.

The company also kept its dividend unchanged for the full year at $ 2.80 per share.

AstraZeneca’s report comes as the UK, European Union and other countries rely heavily on the Covid vaccine in an attempt to end the public health crisis.

The company has announced that it will provide no-profit access to its vaccine for the “duration of the pandemic”, although the timing is uncertain. It is also committed to making the vaccine available on a permanent basis to nonprofits in low and middle income countries. Therefore, the current result did not include vaccine sales.

AstraZeneca, which is listed on the London Stock Exchange, expects sales to grow by a “low-teens percentage” in 2021. The company also forecast “core earnings” per share of between $ 4.75 and $ 5. The guidelines do not include any revenue or profit impact from the sale of the Covid vaccine, AstraZeneca said. The company intends to separate these sales as of the next quarter.

The company’s shares listed in London and the United States changed little on Thursday.

Some controversy

AstraZeneca’s vaccine, developed with Oxford University, was hailed as a game changer along with candidates from other pharmaceutical companies such as Pfizer-BioNTech and Moderna.

Although clinical studies have shown the Oxford-AstraZeneca vaccine to be less effective than its competitors, the fact that it is cheaper and easier to store and transport has proven to be a boon to countries like the UK where it is in January was introduced. The swift introduction of vaccines is seen as critical to reopening economies that have been badly damaged by lockdowns and job losses.

The company has gotten some controversy over its vaccine.

Some drug regulators in Europe have stated that they will not recommend the vaccine for people over 65 – the target age group as the introduction wins steam – because there are supposedly no data to show its effectiveness in this age group.

In addition, South Africa suspended and then abandoned the use of the vaccine because of concerns that it would have limited effectiveness against a variant of the virus found there.

Independent experts advising the World Health Organization on vaccination recommended using AstraZeneca’s vaccine on Wednesday, even in countries where variants exist.

During the test, late-stage clinical trial results highlighting a higher rate of effectiveness after a dosing error highlighted eyebrows among experts, as well as questions about the results and the recommended dosing regimen (like most coronavirus vaccines currently in use) a two-dose shot).

AstraZeneca also got into hot water with the EU when the company said it wouldn’t be shipping as many vaccines to the block as expected in the spring, and blamed teething problems at its manufacturing facilities in Belgium and the Netherlands.

Categories
Health

AstraZeneca races to adapt Covid vaccine as South Africa halts rollout

The dose of Oxford University / AstraZeneca COVID-19 vaccine will be displayed from its box on January 2nd, 2021 at the Princess Royal Hospital, Haywards Heath, West Sussex, UK.

Gareth Fuller | Reuters

Drug maker AstraZeneca is making efforts to adapt its Covid-19 vaccine in light of new variants of the virus. The process is becoming more urgent after a small study found it less effective at protecting against the more virulent strain discovered in South Africa.

The country said it will end the use of the shot in its vaccination program after a study published on Sunday that has not yet been peer-reviewed found the vaccine offered “minimal protection” against mild to moderate illnesses caused by the South African variant will.

Researchers from the University of Witwatersrand and others in South Africa, as well as the University of Oxford, found the study was small, with only about 2,000 volunteers, with a mean age of 31. Oxford University said: “Protection from moderate to severe illness, hospitalization or death could not be assessed in this study because the target group was exposed to such a low risk.”

The vaccine manufacturers had already started developing second-generation Covid vaccines, which will target new variants of the virus. Experts say it shouldn’t be too difficult to tweak existing vaccines to cover mutations, and that they could be adjusted within six weeks.

Sarah Gilbert, professor of vaccinology at Oxford University who developed the vaccine with AstraZeneca, said Sunday that “efforts are being made to develop a new generation of vaccines that will allow protection on new variants as booster jabs redirect if this is the case. ” it turns out that it is necessary to do so. “

“We are working with AstraZeneca to optimize the pipeline that would be required for a strain change should one become necessary. This is the same problem all vaccine developers face and we will continue to monitor the emergence of new variants that arise in the readiness for a future change of burden.

The variant, officially known as the B.1.351 mutation, was first detected in South Africa in October 2020 and has since become dominant in the country.

Several cases have also been found elsewhere of health officials making efforts to stop the spread of the mutation, which has been found to be more contagious. There were already concerns that this variant might be more resistant to coronavirus vaccines developed last year.

With the use of the AstraZeneca-Oxford University jab stopped, the South African government will instead offer vaccines made by Johnson & Johnson and Pfizer.

In late January, Johnson & Johnson reported that its single-dose shot was 57% effective in one of its clinical trials in South Africa, where almost all Covid-19 cases (95%) were due to variant B infection. 1,351 descent. For comparison, the vaccine was found to be 72% effective in the US arm of the study.

Pfizer-BioNTech and Moderna have both reported early signs that their vaccinations offer protection against new known variants of the virus found in South Africa and the UK

On Friday, Oxford University released details of a separate study showing the vaccine was effective against a variant of the virus that was first discovered in south-east England and has now become the dominant strain in the UK

Andrew Pollard, professor of pediatric infection and immunity and lead investigator of the Oxford vaccine study, said data from studies of its vaccine in the UK “shows that the vaccine protects not only against the original pandemic virus, but also against the novel variant B.1.1 .7, which caused the rise in disease across the UK from late 2020. “

Categories
Health

AstraZeneca Shot Discovered to Be Protecting Towards Coronavirus Variant First Seen in U.Okay.

The Covid-19 vaccine developed by AstraZeneca and Oxford University protected people from a new, more contagious variant of coronavirus on a similar level as protection against other lineages of the virus, Oxford researchers said in an article published on Friday.

The paper, which has not yet been peer-reviewed, said the vaccine had an effectiveness of 74.6 percent over the new variant, first detected in the UK and known as B.1.1.7. This was similar, if slightly less than, its effectiveness against other lines of the virus.

The encouraging, if preliminary, results suggest that all five leading vaccines may offer at least some protection against new variants of the virus that is found around the world. However, the increasing evidence suggests that mutant viruses can reduce the effectiveness of vaccines and increase pressure on countries to vaccinate their populations quickly and outperform the globally distributed variants.

In clinical trials, the AstraZeneca-Oxford vaccine protected all participants from serious illness or death.

The Oxford scientists behind the vaccine took weekly swabs from the nose and throat of participants who had taken part in their clinical trial in the UK. To determine the effectiveness of the vaccine against the new variant, they sequenced the virus particles from several hundred swabs between October 1 and January 14. At that time it was known that the new variant was available in Great Britain.

The vaccine had 84 percent effectiveness against other lines of the virus, compared with 74.6 percent against the new variant, although the small sample sizes produced a wide range of estimates.

Andrew Pollard, the lead investigator of the vaccine study at Oxford, said in a statement that data from the study, published Friday, “indicate that the vaccine protects not only against the original pandemic virus, but also against the novel variant B.1.1. 7 that caused the rise in disease across the UK from late 2020 “

The researchers also looked at blood samples from clinical trial participants who had been vaccinated and found that the variant may be better able to evade the antibodies produced by the vaccine.

The variant, first discovered in Great Britain, has since been reported in more than 70 other countries. Public Health England has estimated that the infection rate of the variant is 25 to 40 percent higher than that of other forms of the coronavirus.

Preliminary data from laboratory tests of the Pfizer and Moderna vaccines suggest that they offer good protection against variant B.1.1.7. Novavax, which was sequencing test samples from its participants in clinical trials in the UK while the variant was widespread there, found that its vaccine against variant B.1.1.7 was highly effective.

Covid19 vaccinations>

Answers to your vaccine questions

Am I eligible for the Covid vaccine in my state?

Currently more than 150 million people – almost half of the population – can be vaccinated. But each state makes the final decision on who goes first. The country’s 21 million healthcare workers and three million long-term care residents were the first to qualify. In mid-January, federal officials asked all states to open eligibility to anyone over 65 and adults of any age with medical conditions that are at high risk of becoming seriously ill or dying of Covid-19. Adults in the general population are at the end of the line. If federal and state health authorities can remove bottlenecks in the distribution of vaccines, everyone over the age of 16 is eligible as early as spring or early summer. The vaccine has not been approved in children, although studies are ongoing. It can take months before a vaccine is available to anyone under the age of 16. For the latest information on vaccination guidelines in your area, see your state health website

Is the Vaccine Free?

You shouldn’t have to pay anything out of pocket to get the vaccine, despite being asked for insurance information. If you don’t have insurance, you should still get the vaccine for free. Congress passed law this spring banning insurers from applying cost-sharing such as a co-payment or deductible. It consisted of additional safeguards prohibiting pharmacies, doctors, and hospitals from charging patients, including uninsured patients. Even so, health experts fear that patients will end up in loopholes that make them prone to surprise bills. This may be the case for people who are charged a doctor’s visit fee with their vaccine, or for Americans who have certain types of health insurance that are not covered by the new regulations. When you get your vaccine from a doctor’s office or emergency clinic, talk to them about possible hidden costs. To make sure you don’t get a surprise invoice, it is best to get your vaccine from a Department of Health vaccination center or local pharmacy as soon as the shots become more widely available.

Can I choose which vaccine to get?How long does the vaccine last? Do I need another next year?

That is to be determined. It is possible that Covid-19 vaccinations will become an annual event just like the flu vaccination. Or the vaccine may last longer than a year. We’ll have to wait and see how durable the protection from the vaccines is. To determine this, researchers will track down vaccinated people to look for “breakthrough cases” – those people who get Covid-19 despite being vaccinated. This is a sign of a weakening of protection and gives researchers an indication of how long the vaccine will last. They will also monitor the levels of antibodies and T cells in the blood of people who have been vaccinated to see if and when a booster shot might be needed. It is conceivable that people might need boosters every few months, once a year, or just every few years. It’s just a matter of waiting for the data.

Does my employer need vaccinations?Where can I find out more?

The paper, released on Friday, did not address the protective power of the AstraZeneca vaccine against another fast-spreading variant of coronavirus known as B.1.351, which was first identified in South Africa. Researchers are running similar laboratory tests to measure the effect of this variant on the effectiveness of the vaccine.

AstraZeneca’s vaccine has been approved in nearly 50 countries around the world, but not in the United States, where the Food and Drug Administration is waiting for data from a clinical trial that included more than 30,000 participants, mostly Americans. The results of that study could be available this month, and AstraZeneca is expected to have enough safety data to seek emergency clearance from the FDA by the first week of March.

In the United States, variant B.1.1.7 has been identified in 33 states, but the full extent of its prevalence is unknown due to the lack of a national surveillance program. Federal health officials have warned that it could become the dominant form of the virus in the United States by March.

Categories
Business

The AstraZeneca vaccine is proven to drastically reduce transmission of the virus.

Developed by Oxford University and AstraZeneca, the vaccine not only protects people from serious illness and death, but also significantly slows down the transmission of the virus, according to a new study – a finding that underscores the importance of mass vaccination as a way out of the pandemic.

The study by researchers at Oxford University is the first to document evidence that any coronavirus vaccine can reduce transmission of the virus.

Researchers measured the effects on transmission by wiping participants down each week to look for signs of the virus. In the absence of a virus, it cannot be spread even if someone is infected. And they found a 67 percent reduction in positive swabs among those vaccinated.

The results, detailed by Oxford and AstraZeneca researchers in a non-peer-reviewed manuscript, found that the vaccine could reduce transmission by nearly two-thirds.

Matt Hancock, the UK Health Secretary, hailed the results on Wednesday as “absolutely outstanding”.

“We now know that the Oxford vaccine will also reduce transmission and help us all get out of this pandemic,” Hancock said in an interview with the BBC on Wednesday morning.

The results, he said, “should give everyone confidence that this shock will not only serve to protect you, but also to keep you from passing the virus on to others.”

Some scientists studying the limited information published warned that further analysis of the data would be needed before such broad conclusions could be drawn.

“While this would be extremely welcome news, we need more data before this can be confirmed, so it is important that we all continue to follow social distancing guidelines after vaccination,” said Dr. Doug Brown, executive director of the British Immunology Society.

The Oxford and AstraZeneca researchers also found that a single dose of the vaccine was 76 percent effective against Covid-19. The data was measured three months after the first shot, with no initial three week period required for the protection to take effect.

The encouraging results support the UK and other countries strategy of prioritizing the provision of as many first doses of vaccine as possible and ignore concerns that people will receive their second doses later than originally planned.

The latest data does not affect the debate over whether to further reduce doses of the two US-approved vaccines Pfizer-BioNTech and Moderna, as the data on AstraZeneca’s candidates cannot be transferred to other vaccines.

Some scientists have urged the United States to follow the example of the UK and other countries who have chosen to postpone the second dose of vaccine for up to 12 weeks. But U.S. federal officials refused, saying such a move would not be supported by clinical trial data for the two vaccines currently available nationwide. Tuesday’s results could add to pressure on US health officials to postpone AstraZeneca’s second dose of vaccine, even though it has not yet been approved by the country.

The vaccine appeared to be more effective when the interval between the two shots was longer than the four-week interval originally intended, the Oxford and AstraZeneca researchers found. Among clinical trial participants who received two standard strength doses at least three months apart, the vaccine was 82 percent effective, compared with 55 percent when the doses were given less than six weeks apart.

Covid19 vaccinations>

Answers to your vaccine questions

Am I eligible for the Covid vaccine in my state?

Currently more than 150 million people – almost half of the population – can be vaccinated. But each state makes the final decision on who goes first. The country’s 21 million healthcare workers and three million long-term care residents were the first to qualify. In mid-January, federal officials asked all states to open eligibility to anyone over 65 and adults of any age with medical conditions that are at high risk of becoming seriously ill or dying of Covid-19. Adults in the general population are at the end of the line. If federal and state health authorities can remove bottlenecks in the distribution of vaccines, everyone over the age of 16 is eligible as early as spring or early summer. The vaccine has not been approved in children, although studies are ongoing. It can take months before a vaccine is available to anyone under the age of 16. For the latest information on vaccination guidelines in your area, see your state health website

Is the Vaccine Free?

You shouldn’t have to pay anything out of pocket to get the vaccine, despite being asked for insurance information. If you don’t have insurance, you should still get the vaccine for free. Congress passed law this spring banning insurers from applying cost-sharing such as a co-payment or deductible. It consisted of additional safeguards prohibiting pharmacies, doctors, and hospitals from charging patients, including uninsured patients. Even so, health experts fear that patients will end up in loopholes that make them prone to surprise bills. This may be the case for people who are charged a doctor’s visit fee with their vaccine, or for Americans who have certain types of health insurance that are not covered by the new regulations. When you get your vaccine from a doctor’s office or emergency clinic, talk to them about possible hidden costs. To make sure you don’t get a surprise invoice, it is best to get your vaccine at a Department of Health vaccination center or local pharmacy as soon as the shots become more widely available.

Can I choose which vaccine to get?How long does the vaccine last? Do I need another next year?

That is to be determined. It is possible that Covid-19 vaccinations will become an annual event just like the flu vaccination. Or the vaccine may last longer than a year. We’ll have to wait and see how durable the protection from the vaccines is. To determine this, researchers will track down vaccinated people to look for “breakthrough cases” – those people who get Covid-19 despite being vaccinated. This is a sign of a weakening of protection and gives researchers an indication of how long the vaccine will last. They will also monitor the levels of antibodies and T cells in the blood of people who have been vaccinated to see if and when a booster shot might be needed. It is conceivable that people might need boosters every few months, once a year, or just every few years. It’s just a matter of waiting for the data.

Does my employer need vaccinations?Where can I find out more?

A vaccination strategy that cuts doses by three months “might be the optimum for pandemic vaccine rollout when supplies are limited in the short term,” the researchers wrote.

The newly published study builds on data published late last year. The vaccine was found to be 62 percent effective at two standard strength doses. In these initial findings, the vaccine effectiveness was 90 percent much higher when the first dose of the vaccine was given at half strength.

The researchers from Oxford and AstraZeneca initially attributed the different levels of effectiveness to the lower strength of the initial dose. Gradually, however, they came to a different conclusion: the time between doses was the more likely explanation.

In the United States, the Food and Drug Administration is waiting for data from a clinical trial that involved around 30,000 participants, mostly Americans. The results of this study are expected later this month.

The study is expected to provide AstraZeneca with enough safety data to enable it to obtain approval to make the emergency vaccine available by early March.

The United States has agreed to purchase 300 million doses of the vaccine from AstraZeneca, but neither the company nor the federal government has indicated when and in what quantities those doses will be available after the vaccine is approved.

Categories
Business

Delaying second AstraZeneca vaccine dose does work, examine exhibits

A health worker shows a vial of the Covid-19 coronavirus vaccine from AstraZeneca-Oxford at Patan Hospital near Kathmandu on January 27, 2021.

PRAKASH MATHEMA | AFP | Getty Images

The UK’s decision to postpone AstraZeneca University Oxford’s second shot of coronavirus vaccine has proven to be an effective strategy, according to results from a new study.

Oxford University researchers found that the Covid-19 vaccine was 76% effective at preventing symptomatic infection for three months after a single dose, and that the rate of effectiveness increased with a longer interval before the first and second dose.

“The effectiveness of the vaccine after a single standard dose of the vaccine from the 22nd to the 90th day post-vaccination was 76% … and the modeled analysis showed that protection did not diminish during this initial 3-month period,” said the Study that was reviewed by The Lancet Medical Journal and published as a preprint on Tuesday found.

The effectiveness rate increased to 82.4% when at least 12 weeks were before the second dose. When the second dose was given less than six weeks after the first, the rate of effectiveness was 54.9%.

“These analyzes show that greater vaccine effectiveness is achieved with a longer interval between the first and second dose and that a single dose of vaccine is highly effective in the first 90 days, which further supports current policy,” the report said .

The UK’s current strategy is to vaccinate as many people as possible with a single dose first and postpone the second dose for up to 12 weeks. The idea is that a first dose will provide at least some of the protection and allow more people to have access to the vaccines while their availability is limited.

The decision to delay the administration of a second booster dose has sparked controversy, with some questioning whether it might reduce the effectiveness of the vaccine in preventing severe Covid-19 infection.

However, the UK Joint Committee on Vaccination and Immunization supported the approach. The UK is also delaying the second dose of Pfizer BioNTech vaccine, a move vaccine makers have warned about, arguing that there is no data to support a delay.

The study also provided key data on whether the vaccine reduced transmission of the virus, a previously unknown and crucial question for policy makers looking to lift measures to lock down the economy.

Based on weekly swabs from volunteers in the UK study, a 67% reduction in transmission was found after the first dose of the vaccine.

Effective strategy

This latest study supports the UK Government’s decision and concludes that vaccination programs “aiming to vaccinate a large proportion of the population with a single dose, with a second dose given after a period of three months, are an effective strategy to reduce disease and may be the optimum for pandemic vaccine introduction when supply is limited in the short term. “

The study used additional data from ongoing clinical trials of the vaccine. A separate announcement from AstraZeneca on Wednesday showed that the vaccine also prevented serious illness from Covid-19, with no serious cases and no hospital stays more than 22 days after the first dose.

The vaccine was approved by the UK Medicines Agency on December 30th and, as a shot made in the UK, makes up most of the country’s previously hailed successful vaccination program.

The UK is well on its way to vaccinating its four top priority groups (those over 70, residents and workers in nursing homes, frontline health and social workers and the most clinically vulnerable), which number around 15 million people by mid-February to have.

By February 1, over 9.6 million people had received a first dose of the vaccine, and just under 500,000 had received two doses, according to government figures.

Professor Andrew Pollard, chief investigator of the vaccine study at Oxford and co-author of the study, said, “These new data provide an important review of the intermediate data used by more than 25 regulatory agencies, including MHRA and EMA, to grant vaccine emergency approval.”

“It also supports the policy recommendation of the Joint Vaccination and Immunization Committee for a 12-week prime-boost interval as it seeks the optimal approach to initiation and assures us that people will be protected before 22 days after a single are dose of the vaccine. “

The researchers also hope to release data on the new coronavirus variants in the coming days and expect the results to be broadly similar to those already reported by other vaccine developers: that the current vaccines are effective against mutations in the virus.

Germany, France and Sweden currently do not recommend the AstraZeneca vaccine for people over 65 because of insufficient study data on this age group. However, the vaccine maker and the UK government have defended the sting, saying the data available shows it is safe and effective. Further analysis will be available shortly.

Categories
World News

Covid-19 World Reside Updates: AstraZeneca and Johnson & Johnson Vaccines

Here’s what you need to know:

Video

transcript

Back

transcript

Fauci Warns New Virus Mutations Are a ‘Wake-Up Call’

On Friday, Dr. Anthony S. Fauci warned that new virus variants, despite the global vaccine distribution, should offer a wake-up call to the continuing dangers of the pandemic.

We’re all aware of the variance that we knew dominated — the U.K. B.1.1.7 , the B.1.351 in South Africa and other variants, such as the P.1. in Brazil. When these variants were first recognized, it became clear that we had to look at, in vitro, in the test tube, whether the antibodies that were induced by the vaccines that we had available would actually neutralize these new mutants. Antigenic variation, i.e. mutations that lead to different lineage do have clinical consequences because as you can see, even though the long-range effect in the sense of severe disease is still handled reasonably well by the vaccines, this is a wake-up call to all of us that we will be dealing as the virus uses its devices to evade pressure, particularly immunological pressure, that we will continue to see the evolution of mutants. So that means that we as a government, the companies, all of us that are in this together, will have to be nimble to be able to just adjust readily to make versions of the vaccine that actually are specifically directed towards whatever mutation is actually prevalent at any given time.

On Friday, Dr. Anthony S. Fauci warned that new virus variants, despite the global vaccine distribution, should offer a wake-up call to the continuing dangers of the pandemic.CreditCredit…Doug Mills/The New York Times

Dr. Anthony S. Fauci warned Friday that new clinical trial results from Johnson & Johnson, showing that its vaccine is less effective against a highly infectious variant of the coronavirus circulating in South Africa, were a “wake up call.” He said the virus will continue to mutate, and vaccine manufacturers will have to be “nimble to be able to adjust readily” to reformulating the vaccines if needed.

Dr. Fauci’s warning, at the White House briefing on the virus, comes amid increasing concern about new and more infectious variants of the virus that are emerging overseas and turning up in the United States. This week, officials in South Carolina reported identifying two cases of the variant circulating in South Africa, and officials in Minnesota announced they had found a case of the variant that was first detected in Brazil.

Dr. Rochelle Walensky, the new director of the Centers for Disease Control and Prevention, who was also at the briefing, said another variant, first identified in Britain, has now been confirmed in 379 cases in 29 states. She said officials remained concerned about the variants and were “rapidly ramping up surveillance and sequencing activities” to closely monitor them. Unlike Britain, the United States has been conducting little of the genomic sequencing necessary to track the spread of the variants.

Dr. Walensky also issued a plea to Americans to continue wearing masks and practice social distancing, and to avoid travel. Earlier this month, the C.D.C. warned that the variant circulating in Britain could become the dominant source of infection in the United States and would likely lead to a surge in cases and deaths that could overwhelm hospitals. And given the speed at which the variant swept through that country, it is conceivable that by April it could make up a large fraction of infections in the United States.

“By the time someone has symptoms, gets a test, has a positive result and we get the sequence, our opportunity for doing real case control and contact tracing is largely gone,” she said. “We should be treating every case as if it’s a variant during this pandemic right now.”

Friday’s briefing, the second in what the Biden White House has promised will be thrice-weekly updates on the pandemic, came just hours after Johnson & Johnson reported that while its vaccine was 72 percent effective in the United States, the efficacy rate was just 57 percent in South Africa, where a variant has been spreading.

Public health officials including Dr. Fauci and Dr. Walensky say the emergence of these variants is heightening the urgency of vaccinations. Dr. Fauci also said Friday that children under 16, who are not currently eligible for the vaccine, will likely start getting vaccinated “by late spring or early summer” if small-scale clinical trials show that it is safe and effective to do so.

He noted that the Johnson & Johnson vaccine is 85 percent effective against severe disease, and called the results “very encouraging,” even though the vaccine is not as effective as those by Pfizer and Moderna, which have emergency approval from the Food and Drug Administration. Johnson & Johnson will now seek its own emergency approval.

“This really tells us that we have now a value-added additional vaccine candidate,” he said.

But Dr. Walensky offered a far more sobering observation. While the daily number of new virus cases has been declining, the figures were still much higher than a period last summer, and deaths currently remain worrisome.

According to data compiled by The New York Times, new virus cases have averaged about 160,000 a day in recent days, compared to about 40,000 new cases a day around early September. As of Thursday, the seven-day average of new deaths was more than 3,200 a day, still near peak levels. The daily death toll has topped 4,000 deaths six times in the United States, including twice this week.

At Wednesday’s briefing by the Biden virus team, Jeffrey D. Zients, Mr. Biden’s coronavirus response coordinator, said the United States is lagging far behind other countries in sequencing the genomes of the new variants — a delay he called “totally unacceptable.” Dr. Walensky said she is working to change that.

“We have scaled up surveillance dramatically just in the last ten days, in fact, but our plans are more than what we’ve done so far,” Dr. Walensky said, adding that the C.D.C. is now asking every state to track for worrisome variants and sequence at least 750 samples from patients per week. In addition, she said, the agency has seven collaborations with universities to scale up surveillance to cover thousands of samples per week.

United States › United StatesOn Jan. 28 14-day change
New cases 165,264 –34%
New deaths 3,868 –2%
World › WorldOn Jan. 28 14-day change
New cases 603,392 –22%
New deaths 16,817 +4%

U.S. vaccinations ›

Where states are reporting vaccines given

Video

transcript

Back

transcript

E.U. Plans to Halt Vaccine Exports Until Supply Contracts Are Met

The European Union announced a plan that would effectively stop AstraZeneca from shipping Covid-19 vaccine doses manufactured in the bloc to other countries until its E.U. supply contracts are met.

The commission has adopted a strictly targeted measure that will allow us to gather accurate information about the production of vaccines and where manufacturers intend to ship them. The measure is time-limited and specifically applies to those Covid-19 vaccines that were agreed by advance purchase agreements. The measure is intended to run until the end of March. The aim is to provide us immediately with full transparency, transparency that until now has been lacking, and what Europeans expect. And if needed, it also will provide us with a tool to ensure vaccine deliveries.

Video player loadingThe European Union announced a plan that would effectively stop AstraZeneca from shipping Covid-19 vaccine doses manufactured in the bloc to other countries until its E.U. supply contracts are met.CreditCredit…Dinuka Liyanawatte/Reuters

BRUSSELS — The European Union on Friday announced plans to effectively halt any attempt by AstraZeneca to move vaccine doses manufactured in the bloc to other countries unless it first meets its supply obligations to the bloc’s 27 member states.

The move, the latest escalation in a dispute between the bloc and the pharmaceutical company over reduced supplies, came as the European Union’s drug regulator authorized AstraZeneca’s coronavirus vaccine for use across its member states.

AstraZeneca said this month that it would significantly cut its promised delivery supply of the jab to the European Union as of mid-February. That pitted the bloc against Britain, a former member, which has been receiving a steady flow of vaccine doses from AstraZeneca since approving it well ahead of the E.U., in early December.

The AstraZeneca vaccine was developed in cooperation with Britain’s University of Oxford. The European Union accused the pharmaceutical company of using its promised doses to serve Britain, despite having paid the company about $400 million in October to help it scale up its capabilities and produce doses ahead of authorization.

The policy announced by the European Commission on Friday, presented as a “transparency tool,” will ask all pharmaceutical companies manufacturing coronavirus vaccines in factories within the bloc — currently Pfizer and AstraZeneca — to submit paperwork alerting the European authorities of any intention to move their products to non-E.U. countries. It will be in place until the end of March and will not apply to exports to poorer countries.

The Commission said it reserved the right to block such exports if it determined that the pharmaceutical companies were not meeting their contractual obligations with the E.U. first.

The measure could theoretically also affect Pfizer clients, but the Commission has said it is happy with how that company has handled a supply disruption in its Belgian factory that is setting back deliveries. The company has spread the pain among its clients, which include the E.U., Britain and Canada.

The Commission said that AstraZeneca’s decision to maintain delivery volumes to Britain while slashing its deliveries to the E.U., after a problem arose in a Belgium-based plant, was in bad faith and breach of the company’s contractual obligations.

The company’s chief executive responded that he regretted the situation, but that his company had not committed to a specific schedule, but rather to a vow to make its “best effort.”

The Commission dismissed the claim, and published a heavily redacted version of the contract with AstraZeneca. The contract affords the company many standard protections in case it fails to deliver, but includes some clauses that could be seen as favoring the E.U. interpretation that AstraZeneca is obligated to turn to other factories, including in Britain, to fulfill its delivery promises.

The matter is further complicated by regulation issues: The European drug regulator, the European Medicines Association, received an application for authorization from AstraZeneca on Jan. 12, nearly two weeks after the company received emergency authorization in Britain. The E.U. agency was expected to announce approval of use of the vaccine later on Friday.

The dispute with AstraZeneca is occurring against a backdrop of severe shortages of doses at vaccination centers across Europe. French and German regions have reported that they are nearly running out, and the Madrid region of Spain has suspended its rollout for at least two weeks until fresh deliveries arrive.

The E.U. regulator stopped short of imposing an age cap on the use of the vaccine, despite concerns about a paucity of data on the vaccine’s efficacy in people age 65 and older.

Video

transcript

Back

transcript

N.Y.C. Indoor Dining to Reopen on Valentine’s Day

On Friday, Gov. Andrew M. Cuomo announced that indoor dining in New York City could resume at up to 25 percent capacity starting on Valentine’s Day.

New York City restaurants, on our current trajectory, we can reopen indoor dining at 25 percent on Valentine’s Day. The restaurants want a period of time so they can notify workers. They can get up to speed for indoor dining, order supplies, etc. So we’re saying indoor dining. 25 percent on Valentine’s Day. Going forward, we are very excited about the possibility of reopening venues with testing. Restaurants are opened on Valentine’s Day. You could make a reservation now or plan dinner on Valentine’s Day, you propose on Valentine’s Day. And then you can have the wedding ceremony March 15, up to 150 people. People will actually come to your wedding because you can tell them with the testing, it will be safe. Everybody there will be tested, and everybody will be safe.

Video player loadingOn Friday, Gov. Andrew M. Cuomo announced that indoor dining in New York City could resume at up to 25 percent capacity starting on Valentine’s Day.CreditCredit…Clay Williams for The New York Times

Indoor dining will resume with limited capacity in New York City restaurants next month, Gov. Andrew M. Cuomo announced on Friday, more than a month after he had banned it to combat a second wave of the coronavirus.

Starting on Feb. 14, the city’s restaurants can seat customers indoors at 25 percent maximum capacity, he said.

The announcement was a source of hope for the restaurant industry, an important driver of the city’s economic engine, which has been decimated by ever-changing virus-induced restrictions that have forced many restaurants and bars to go out of business and caused thousands of workers to lose their jobs.

After shutting down restaurants in March, Mr. Cuomo allowed the city’s indoor dining to restart in late September. He prohibited it again in mid-December as holiday travel threatened to increase transmission of the virus and overwhelm hospitals.

Restaurants and bars that have stayed afloat have relied on takeout and delivery, as well as outdoor dining, an increasingly untenable option as the frigid winter advances.

Starting March 15, wedding receptions with up to 150 attendees will be allowed in the state, the governor said, as long as the venues are at no more than 50 percent capacity. The gatherings would have to be approved in advance by a local health department, and all attendees will have to be tested.

“We want to use testing as the key to reopening events,” Mr. Cuomo said.

The governor’s decisions come at an incredibly precarious phase in the state’s battle against the virus, which has killed more than 42,500 people in New York State, a one-time center of the pandemic.

Yankee Stadium will open its doors as a mass vaccination site, Mr. Cuomo said, pointing to high positivity rates in the Bronx. He did not specify a time frame.

Participating in a Johnson & Johnson vaccine trial at the Desmond Tutu H.I.V. Foundation Youth Center near Cape Town last month.Credit…Joao Silva/The New York Times

Johnson & Johnson said on Friday that its one-dose coronavirus vaccine provided strong protection against Covid-19, offering the United States a third powerful tool in a race against a worldwide rise in virus mutations.

But the results came with a significant cautionary note: The vaccine’s efficacy rate dropped from 72 percent in the United States to 57 percent in South Africa, where a highly contagious variant is driving most cases. Studies suggest that this variant also blunts the effectiveness of Covid vaccines made by Pfizer-BioNTech, Moderna and Novavax.

The variant has spread to at least 31 countries, including two cases documented in the United States this week.

Johnson & Johnson said it planned to apply for emergency authorization of its vaccine from the Food and Drug Administration as soon as next week, putting it on track to receive clearance later in February.

“This is the pandemic vaccine that can make a difference with a single dose,” said Dr. Paul Stoffels, the company’s chief scientific officer.

The company’s announcement comes as the Biden administration is pushing to immunize Americans faster even as vaccine supplies tighten. White House officials have been counting on Johnson & Johnson’s vaccine to ease the shortfall. But the company may have as few as seven million doses ready when the vaccine is authorized, according to federal health officials familiar with its production, and no more than 32 million doses by early April.

The variant from South Africa, known as B.1.351, could make the vaccine push tougher. Given the speed at which the variant swept through that country, it is conceivable that it could make up a large fraction of infections in the United States by April and therefore undermine the effectiveness of available vaccines.

The two vaccines approved by the U.S. government have been found to be less effective against the B.1.351 variant in clinical trials, a development that has unsettled federal officials and vaccine experts.

Many researchers say it is imperative to vaccinate people as quickly as possible. Lowering the rate of infection could thwart the more contagious variants while they are still rare.

“If ever there was reason to vaccinate as many people as expeditiously as we possibly can with the vaccine that we have right now, now is the time,” said Dr. Anthony S. Fauci, the government’s top infectious disease expert. “Because the less people that get infected, the less chance you’re going to give this particular mutant a chance to become dominant.”

A pregnant woman being vaccinated in Tel Aviv. Credit…Jack Guez/Agence France-Presse — Getty Images

The World Health Organization on Friday changed its guidance for pregnant women considering a Covid-19 vaccine, abandoning opposition to immunization for most expectant mothers unless they were at high risk.

The change followed an outcry to the W.H.O.’s previous stance, which stated that the organization did “not recommend the vaccination of pregnant women” with the vaccines made by Pfizer-BioNTech and Moderna.

Several experts had expressed disappointment on Thursday with the W.H.O.’s earlier position. The experts noted that it was inconsistent with guidance on the same issue from the U.S. Centers for Disease Control and Prevention, and would confuse pregnant women looking for clear advice.

The vaccines made by Pfizer-BioNTech and Moderna, while they have not been tested in pregnant women, have not shown any harmful effects in animal studies. And the technology used in the vaccines is generally known to be safe, experts said.

The W.H.O.’s new phrasing reflects this information:

“Based on what we know about this kind of vaccine, we don’t have any specific reason to believe there will be specific risks that would outweigh the benefits of vaccination for pregnant women.” The recommendation is now closely aligned with the C.D.C.’s stance.

Experts praised the shift, welcoming agreement between the world’s leading public health organizations on this important issue.

“I was very pleased to see that W.H.O. changed their guidance regarding offering the Covid-19 vaccine to pregnant women,” said Dr. Denise Jamieson, an obstetrician at Emory University and a member of the Covid expert group with the American College of Obstetrics and Gynecology. The association was among the many women’s health organizations that had urged Pfizer and Moderna to speed up vaccine tests in pregnant women.

“The more permissive W.H.O. language provides an important opportunity for pregnant women to get vaccinated and protect themselves from the severe risks of Covid-19,” Dr. Jamieson said. “This impressively rapid revision by W.H.O. is good news for pregnant women and their babies.”

Pregnant women have traditionally been excluded from clinical trials, leaving a dearth of scientific data on the safety of drugs and vaccines in women and their unborn children. Vaccines are generally considered to be safe, and pregnant women have been urged to be immunized for influenza and other diseases since the 1960s, even in the absence of rigorous clinical trials to test them.

Pfizer will test its vaccine in pregnant women over the next few months, according to a spokeswoman for the company. And Moderna plans to establish a registry to observe side effects in women who were immunized with its vaccine.

Border police at the international airport in Frankfurt, Germany.Credit…Thomas Lohnes/Getty Images

Germany on Friday announced its plans to restrict incoming travel from a handful of countries, including Britain and Ireland, in an attempt to curb the spread of infectious coronavirus variants, going beyond the measures recommended by the European Union.

“It’s about stopping the entry of a highly infectious virus,” Horst Seehofer, Germany’s interior minister, said on Thursday, a day before the federal cabinet approved the restrictions.

Under the new travel ban — which also applies to passengers coming from Portugal, Brazil, South Africa, Lesotho and Eswatini (formerly known as Swaziland) — German residents will be able to return home, but non-German residents from the areas in question will be refused entry, even with a negative coronavirus test.

While multiple known infectious variants have been found in Germany, including the B.1.1.7 variant at a hospital in Berlin, which then had to go into lockdown, health authorities believe they can still prevent variants from spreading and driving new infections.

The change will go into effect over the weekend and will be in place until at least Feb. 17. It follows a temporary halt in travel for all passengers coming from the United Kingdom and South Africa, which was lifted a few days after it was enacted. All nonessential travel remains discouraged.

After more than six weeks of a strict lockdown — during which restaurants, bars, nonessential shops and most schools have been shuttered — Germany is starting to show slight improvement in its daily case numbers. On Thursday, health authorities reported 14,022 infections in a 24-hour period, nearly 4,000 less than the amount registered one week earlier.

Video

transcript

Back

transcript

Canadian Airlines Suspend Flights to the Caribbean and Mexico

Prime Minister Justin Trudeau of Canada announced on Friday that major airlines have agreed to suspend flights to sunny vacation spots as new coronavirus quarantine measures are put into place.

The government and Canada’s main airlines have agreed to suspend service to some destinations right away. Air Canada, WestJet, Sunwing and Air Transat are canceling air service to all Caribbean destinations and Mexico starting this Sunday up until April 30. Starting next week, all international passenger flights must land only at the following four airports: Vancouver, Calgary, Toronto and Montreal. In addition to the pre-boarding test we already require, as soon as possible in the coming weeks, we will be introducing mandatory P.C.R. testing at the airport for people returning to Canada. Travelers will then have to wait for up to three days at an approved hotel for their test results, at their own expense, which is expected to be more than $2,000. We will also, in the coming weeks, be requiring non-essential travelers to show a negative test before entry at the land border with the U.S. And we’re working to stand up additional testing requirements for land travel.

Video player loadingPrime Minister Justin Trudeau of Canada announced on Friday that major airlines have agreed to suspend flights to sunny vacation spots as new coronavirus quarantine measures are put into place.CreditCredit…Blair Gable/Reuters

Prime Minister Justin Trudeau of Canada announced Friday that flights between the country and several sunny vacation spots will be suspended, as new testing and quarantining measures are put in place for most air travelers entering Canada.

After previously requiring that air travelers coming to Canada for nonessential purposes show evidence of a negative coronavirus test result from within 72 hours before being allowed on planes, Mr. Trudeau said that they will now also be tested when they land upon their return to Canada. Travelers will have to wait for the results of that second test for three days in a government hotel at their own expense under the new measures.

“Now is just not the time to be flying,” Mr. Trudeau said at an outdoor news conference. “By putting in place these tough measures now, we can look forward to a better time when we can all plan those vacations.”

During most of the pandemic, international flights leaving and entering Canada have been limited to four airports. The flights that are canceled under the new order mainly service resort areas in Mexico and the Caribbean. Airlines are making arrangements to return Canadians who are already in those areas, Mr. Trudeau said.

In December, Canada temporarily stopped air travel to and from the United Kingdom following the appearance there of a new variant of the coronavirus.

Mr. Trudeau estimated that the mandatory three-day stay would cost travelers about 2,000 Canadian dollars, or about $1,570. Travelers with a negative test result will then need to quarantine for 11 more days at their homes. Those with positive test results will be sent to government facilities.

Travelers entering Canada on nonessential trips at land border crossings will also soon be tested, Mr. Trudeau said. They have long been required to quarantine for two weeks.

The premiers of Ontario and Quebec, the country’s two most populous provinces, have been pressuring Mr. Trudeau to introduce testing upon arrival at airports and introduce further flight restrictions. Several Canadian politicians and officials have also come under severe criticism and, in some cases, resigned their positions for traveling outside of the country for vacation.

Mr. Trudeau acknowledged that the percentage of Covid-19 cases in Canada linked to foreign travel is “extremely low.” But he said that the new restrictions should limit the risk posed by new variants of the virus.

“These variations represent a very real challenge,” Mr. Trudeau said.

Columbia University has mostly offered online instruction during the pandemic, and allowed only a sliver of students to live on campus or attend in-person classes. Credit…Mark Lennihan/Associated Press

Over 1,100 undergraduate and graduate students at Columbia University have pledged to withhold their tuition for the spring semester to demand a discount for what they see as a lost spring term.

While some universities have brought students back to campus, Columbia has mostly offered online instruction for students and allowed only a sliver of them to live on campus or attend in-person classes.

In response, students are asking the university to reduce their total costs — including tuition, fees, and room and board — by at least 10 percent, following suit of several schools including Georgetown University, Princeton University and Williams College. Columbia College, the university’s undergraduate school, can cost more than $80,000 a year for students not receiving financial aid.

Strike organizers said that both graduate and undergraduate students were participating; the university has more than 31,000 students.

“It’s a reasonable demand,” said Matthew Gamero, 19, a sophomore who is one of the strike organizers. “This is about the university providing an education of its worth, and to have it online is certainly not what we’re paying for.”

“This is a moment when an active reappraisal of the status quo is understandable, and we expect nothing less from our students,” the university said in a statement. “Their voices are heard by Columbia’s leadership, and their views on strengthening the University are welcomed.”

A tuition discount is only one of a series of demands made by strikers. They have also called on the university to reduce funding for campus policing, improve working conditions for graduate students and provide aid for the surrounding West Harlem community.

The tuition strike was officially kicked off after the spring term bill was due last Friday. For undergraduates, the university could impose a $150 late fee and prevent them from registering for summer or fall classes. The university could also penalize seniors by withholding their diplomas until their balance is paid.

People walk near the Eiffel Tower in Paris the day after Christmas. France will shut its borders to nonessential travel from countries outside the European Union on Sunday.  Credit…Michel Euler/Associated Press

France said on Friday that it would close its borders to non-European Union countries as cases rise and the government struggles to avoid a new lockdown.

Jean Castex, the French prime minister, said that all travel between France and nations outside of the E.U. would be banned starting on Sunday, with exceptions made only for urgent matters. All travelers from E.U. countries, except for cross-border workers, will have to present a negative coronavirus test to enter the country, Mr. Castex added.

Speculation about new restrictions had been growing in France over the past week, with a flurry of conflicting and often confusing information from officials, and many were expecting President Emmanuel Macron to replace the current 6 p.m. to 6 a.m. curfew with a new lockdown.

Speaking after a special cabinet meeting in Paris, Mr. Castex acknowledged France faced a “strong risk of acceleration of the epidemic” because of the more contagious British and South African variants of the virus, and said debates over a new nationwide lockdown were “legitimate.”

“But we all know the very heavy toll it has on the French, on all counts,” he said of a lockdown. “This evening, we consider that in view of the numbers over the past few days, we can still give ourselves a chance to avoid one.”

The variants that emerged in Britain and South Africa have both been detected in France, and the country’s vaccination campaign has slowed amid disruptions in the E.U. supply chain. The number of new cases has continued to rise in France over the past few weeks, with nearly 23,000 new cases reported on Friday, though they have not skyrocketed like they have for some of France’s neighbors.

Britain, which has faced record numbers of cases and deaths, tightened its travel restrictions on Wednesday, requiring British citizens arriving from 22 high-risk countries to quarantine in hotels for 10 days at their own expense. England entered its latest lockdown at the start of January.

The European Commission, the executive arm of the European Union, recommended on Monday restricting nonessential travel in a bid to prevent blanket border closures, which can obstruct trade and the movement of cross-border workers.

“We need to keep safe and discourage nonessential travel,” Ursula von der Leyen, the president of the commission, wrote on Twitter, citing the danger of new variants circulating.

Mr. Castex also announced the closure of the country’s largest malls that do not sell groceries, starting on Sunday, and increased police checks on curfew violations and establishments like restaurants that open illegally. Companies will be further encouraged to have their employees work from home, he said.

“Our goal is to do everything to avoid a new lockdown, and the next few days will be decisive,” Mr. Castex said.

A woman walks past a sorority house on the University of Michigan campus, where more than a dozen cases of a coronavirus variant were found.Credit…Shannon Stapleton/Reuters

Fourteen students at the University of Michigan have contracted a highly contagious variant of the coronavirus, leading health authorities to issue a stay-at-home recommendation for students living on and off campus.

Students were advised to not leave their residences until Feb. 7, except to attend classes, seek medical treatment or run essential errands.

The outbreak of the variant, first detected in Britain and known as B.1.1.7, appears to have started with a student who traveled to the United Kingdom over the winter break, according to Susan Ringler-Cerniglia, a spokeswoman for the Washtenaw County Department of Health.

The first case on the university’s campus was identified on Jan. 16 after the student tested positive and notified officials that he or she had traveled to an area where the variant was prevalent. That prompted additional sequencing that identified the student was infected with the variant, Ms. Ringler-Cerniglia said.

Since then an additional 13 students who are positive with the same variant have been identified. One of them had visited a local indoor mall and a grocery store before testing positive, leading authorities to issue a public notice to people who had visited those locations, asking them to seek testing.

Rick Fitzgerald, a spokesman for the university, said that all the infected students were in isolation with mild symptoms.

The stay-at-home recommendation announced by the Washtenaw County Health Department this week applies to the Ann Arbor campus but not to the broader community.

“More stringent, mandatory actions may be imposed if this outbreak continues to grow and additional variant clusters are identified,” the health department said in a memo to university officials on Wednesday.

Michigan athletics also imposed a two-week pause in competitions and practice, citing the emergence of the variant as the reason. Five of the cases involved individuals connected to the athletic program.

The variant is regarded as 50 percent more transmissible than the standard form of the virus but it isn’t more dangerous, and the vaccines that are currently on the market appear to be effective against it.

Since Michigan’s winter session began Jan. 19, the university has identified a total of 175 coronavirus cases, including the 14 cases of the variant.

Cardinal Timothy Dolan blessed the crowds from the steps of St. Patrick’s Cathedral in Manhattan after Easter Mass in 2016.Credit…Kathy Willens/Associated Press

Cardinal Timothy M. Dolan, the leader of the Roman Catholic Archdiocese of New York, was in quarantine on Friday after he interacted last week with a person who later tested positive for the coronavirus, according to a spokesman.

In a statement, the archdiocese said the cardinal “has not tested positive, feels fine, and has no symptoms.” Joseph Zwilling, a spokesman for the archdiocese, said the cardinal is tested regularly, had tested negative since the interaction, and would be tested again “in a few days.” He did not specify what kind of tests were used nor the timing of when he cardinal was tested after the interaction.

Tests taken too soon after exposure may return false negative results, because the virus has not yet had time to build up to detectable levels. People are thought to carry the largest quantity of virus around the time their symptoms appear, if they experience symptoms at all.

The cardinal’s quarantine had not previously been announced by the archdiocese. Mr. Zwilling said the cardinal had been in quarantine since Wednesday but that no announcement had been made because the infected individual had not received the results of their coronavirus test until Thursday.

“He did not have any public events, and all of his meetings were via Zoom, etc.,” Mr. Zwilling said in an email, referring to the cardinal. “We are announcing today because the exposure was confirmed, and the first public events — Mass tomorrow evening and Sunday morning — were coming up, and he will obviously not be present for those events.”

The cardinal will “continue to follow health and safety protocols as instructed by medical professionals, as will others on his staff who also had close contact with this individual,” the statement said.

Cardinal Dolan is one of the most influential figures in American Catholicism, and the Archdiocese of New York is the second-most populous in the United States, with more than 2.8 adherents living in a territory that stretches from Staten Island into the Hudson Valley.

He had celebrated Mass last Sunday at Saint Patrick’s Cathedral and interacted with other priests and parish personnel, all wearing masks, at that time, according to online video of the service.

global roundup

Video

transcript

Back

transcript

W.H.O. Delivers Update on China Visit

On Friday, the World Health Organization reviewed the details of its investigation into the origin of the coronavirus in China, and what it hopes to learn from the visit.

There is a very long list of site visits planned and face-to-face meetings continue. The — the visits will include the Wuhan Institute of Virology, other labs, the Wuhan markets, early responders, hospitals in which the first clusters of cases occurred. We continue to be hopeful that all of the data and all of the meetings that they need will be had. And and just to reconfirm that all hypotheses are on the table, and we’re looking forward, hopefully, to a successful conclusion of the mission. Success in the case of animal human interface investigations is not measured necessarily in absolutely finding a source on the first mission. This is a complicated business, what we need to do is gather all of the data, all of the information, summarize all of these discussions and come to an assessment as to how much more we know about the origins of the disease, and what further studies may be needed for the release of.

Video player loadingOn Friday, the World Health Organization reviewed the details of its investigation into the origin of the coronavirus in China, and what it hopes to learn from the visit.CreditCredit…Hector Retamal/Agence France-Presse — Getty Images

After months of delays, a team of World Health Organization scientists tracing the pandemic’s origin began its field work on Friday in Wuhan, the Chinese city where the coronavirus was first detected.

The W.H.O. said its team of 15 experts planned to visit hospitals, laboratories and a live animal market over the next several weeks in Wuhan, a city of 11 million, where the virus was detected in late 2019.

“As members start their field visits on Friday, they should receive the support, access and the data they need,” the W.H.O. said on Twitter. “All hypotheses are on the table as the team follows the science in their work to understand the origins of the #COVID19 virus.”

The Chinese government had repeatedly sought to delay the inquiry, apparently out of concern that the experts would draw attention to the government’s early missteps in handling the outbreak. But it relented under mounting global pressure.

The W.H.O. experts were first asked to undergo 14 days of quarantine in Wuhan, which ended on Thursday.

They plan to speak with some of the first patients to show symptoms of Covid-19, as well as with medical workers and Chinese scientists, according to the W.H.O. Their fieldwork will include a visit the Huanan Seafood Wholesale Market, where some of the first cases were detected.

They will also visit the Wuhan Institute of Virology and a laboratory operated by Chinese Center for Disease Control and Prevention.

The question of the pandemic’s origin has caused friction between China and the United States, with officials in each country at times blaming the other for unleashing the virus on the world.

Jen Psaki, the White House press secretary, said on Wednesday that the United States hoped for a “robust and clear” international investigation.

Chinese officials, in response, defended the country’s handling of the inquiry.

“We hope the U.S. side will work with China, take on a responsible attitude and respect facts, science and the diligent work of W.H.O. experts,” Zhao Lijian, a spokesman for the Chinese foreign ministry, said at a news conference in Beijing on Thursday.

  • Chinese officials said on Friday that several passengers traveling to China from the United States had falsified coronavirus test results so they could gain entry to the country. The Chinese consulate in San Francisco said the passengers had “changed their test results from positive to negative” and that other travelers had lied about test results. The consulate did not provide details about the passengers or the punishments they might face. China maintains strict border control rules, including a requirement that travelers present results from antibody and nucleic acid tests before they fly. The consulate said the passengers had violated public health laws. “The way they put others at risk is odious,” the statement said.

  • Vietnam recorded nine more coronavirus cases on Friday, including one in the capital, Hanoi, as a new outbreak spread beyond the two northern provinces where infections had first been detected a day earlier. Officials put the number of cases from the latest outbreak at 93 as of Friday afternoon but said that it could reach 30,000, nearly 20 times the number of cases that Vietnam detected during the entire first year of the pandemic. Vietnam has been among the most successful countries in containing the virus, with strict border controls, mask-wearing, contact tracing and isolation of infected people. The latest outbreak comes as officials from the governing Communist Party meet to select the country’s new leaders, an event held once every five years.

  • Hungary’s medicine authority has approved the coronavirus vaccine developed by the Chinese company Sinopharm. “This means that in addition to Pfizer, Moderna, Sputnik and AstraZeneca, we can also count on Sinopharm,” said Dr. Cecilia Muller, the country’s chief medical officer. “We trust that these vaccines will be readily available in large quantities and the immunization process will be completed in larger numbers in less time.” The country’s foreign minister later announced that it had purchased five million doses of the vaccine. Regarding the options, Prime Minister Viktor Orban expressed enthusiasm for the Chinese vaccine on Friday. “I will wait for the Chinese vaccine,” he said. “I trust that one the most.”

  • Spain’s first case of the South African variant of Covid-19 was detected in the port city of Vigo, in the northwestern region of Galicia. Health authorities in Galicia said a 30-year old man who works in the shipping industry returned from a recent work trip to South Africa and tested positive for the variant earlier this month. He had light symptoms and was not hospitalized, they said.

Registered nurses demonstrated against unsafe staffing practices at Good Samaritan Hospital in San Jose, Calif., in December. Credit…Sarahbeth Maney for The New York Times

The unions representing the nation’s health care workers have emerged as increasingly powerful voices during the still-raging pandemic.

With more than 100,000 Americans hospitalized and many among their ranks infected, nurses and other health workers remain in a precarious frontline against the coronavirus and have turned again and again to unions for help.

Nurses across the country from various unions are participating in dozens of strikes and protests. National Nurses United, the country’s largest union of registered nurses, held a “day of action” on Wednesday with demonstrations in more than a dozen states and Washington, D.C., as it starts negotiations at hospitals owned by big systems like HCA, Sutter Health and CommonSpirit Health.

“It’s so overwhelming. It’s unlike anything I’ve ever seen before,” said Erin McIntosh, a nurse at Riverside Community Hospital in Southern California, a part of the country that has been among the hardest hit by a surge in cases. “Every day I’m waist-deep in death and dying.”

Hospitals said the unions are playing politics during a public health emergency and say they have no choice but to ask more of their workers.

But health care workers say they have been bitterly disappointed by their employers’ and government agencies’ response to the pandemic. Dire staff shortages, inadequate and persistent supplies of protective equipment, limited testing for the virus and pressure to work even if they might be sick have left many workers turning to the unions as their only ally. The virus has claimed the lives of more than 3,300 health care workers nationwide, according to one count.

Credit…Joshua Lott/Reuters

“We wouldn’t be alive today if we didn’t have the union,” said Elizabeth Lalasz, a Chicago public hospital nurse and steward for National Nurses United.

Despite the decades-long decline in the labor movement and the small numbers of unionized nurses, labor officials have seized on the pandemic fallout to organize new chapters and pursue contract talks for better conditions and benefits. National Nurses organized seven new bargaining units last year, compared to four in 2019. The Service Employees International Union, which represents Mrs. McIntosh, also says it has seen an uptick in interest.

Tyler Perry in 2019.Credit…Frederic J. Brown/Agence France-Presse — Getty Images

With the pandemic exposing racial disparities in the United States — Black people have died of Covid-19 at nearly three times the rate of white people, according to the Centers for Disease Control and Prevention — health officials have been working to promote vaccinations in Black communities, and to combat doubt.

So doctors in Atlanta turned to Tyler Perry — a popular and prolific actor, director and studio head — to spread the word to Black audiences that the vaccine was harmless. He agreed to interview the experts, turning it into a TV special that aired Thursday night on BET. On the show, he peppered doctors from Grady Health System with questions about the safety of the vaccine, how it was developed, how it was tested and how it works.

At the end of the interview, with his sleeve pulled up, Perry got the jab as cameras rolled.

Perry is one of the most powerful people in the entertainment industry. He built his fortune portraying the character of Madea, a tart-tongued and irreverent matriarch, onstage and onscreen, before retiring her in 2019 to concentrate on other projects, which include running his 330-acre studios in Georgia.

Skepticism about the Covid-19 vaccine among Black people has been deeply concerning to health officials. A recent study by the Kaiser Family Foundation found that one in three Black people was hesitant about vaccine. A recent CNN analysis found that Black and Latino Americans were getting the vaccine at significantly lower rates than white people — rates attributed to, among other factors, lack of access to health care for many Black people, but also to an entrenched mistrust about the medical establishment.

On the BET special, Perry spoke of episodes in history that have led to a lack of faith in the medical establishment and the government, among them the Tuskegee Syphilis Study, in which doctors allowed syphilis to progress in Black men by withholding treatment from them, and the case of Henrietta Lacks, a Black woman who died of cervical cancer in 1951, whose cells were used in research without her knowledge or consent.

“We as Black people have healthy hesitation when it comes to vaccinations and so on and so forth, and even disease,” he said.

Perry said he didn’t want people getting vaccinated just because he had. “What I want to do is give you the information, the facts,” he said. “There’s a lot of misinformation out there.”

Video

transcript

Back

transcript

New York City Sets ‘Aggressive Goal’ of 5 Million Vaccinations by June

Mayor Bill de Blasio said the city is aiming to vaccinate 5 million New Yorkers against Covid-19 by June. He also announced plans to bring city workers back to offices in May and reopen schools for all students in September.

We’re going for an aggressive goal, five million New Yorkers vaccinated by June. I am absolutely certain we can do it so long as we have the vaccine. And I am more and more confident because the actions the Biden administration, because the Johnson Johnson vaccine is coming, more and more confident that we will have what we need. I’m going to push hard on the federal government to get every pharmaceutical company in America into this work because they’re not right now. The federal government needs to ensure that they are required to produce vaccine, whether they’re the originator of the vaccine or not. So long as we have the supply, we can reach five million new Yorkers in June, get to a point of community immunity. And we’re going to bring back our city workforce in May and after, because obviously so many are on the job right now. But the folks who work in our offices and do so much important work, we want them back. We want to send a signal to this whole city. We’re moving forward. We want to see the private sector bring workforces back. We are going to have an entirely different situation as we proceed into the spring. By the end of the spring, I think you’re going to see something very different. And we’re going to a great group of folks out there, our vaccine for all core leading the way. Now, a lot of different pieces matter, and one of the most crucial ones that matters to us for today, for our parents, for our families, for our future, tomorrow — our schools, one of the things that says most clearly, we are back is our schools. And so in September, our schools come back fully. We focus on helping kids overcome that Covid achievement gap. Our 2021 student achievement plan focuses on the academic side, but also the emotional side, the mental health needs of our kids after everything they’ve been through.

Video player loadingMayor Bill de Blasio said the city is aiming to vaccinate 5 million New Yorkers against Covid-19 by June. He also announced plans to bring city workers back to offices in May and reopen schools for all students in September.CreditCredit…James Estrin/The New York Times

In his final State of the City address, Mayor Bill de Blasio offered a sprawling vision of New York City’s recovery from a pandemic that has taken tens of thousands of lives and destroyed the city’s economy.

The mayor committed to accelerating the city’s vaccination efforts and set a goal of inoculating five million New Yorkers by June.

“We’re going for an aggressive goal,” Mr. de Blasio said at a news conference on Friday morning, adding that “I am absolutely certain we can do it, so long as we have the vaccine.”

On Friday, Mr. de Blasio said that, given an adequate supply of the vaccine, the city could vaccinate half a million people per week, and that he planned to reopen vaccination sites that had closed as more vaccine became available.

Johnson & Johnson announced on Friday that their vaccine was very effective at preventing the virus, but that its efficacy dropped steeply against a more contagious variant in South Africa. White House officials have been counting on Johnson & Johnson’s vaccine, to ease the shortfall of vaccine supply. Unlike the federally authorized vaccines made by Pfizer and Moderna, Johnson & Johnson’s vaccine is effective after only one dose. But the company may only have about seven million doses ready when the F.D.A. decides whether to authorize it, according to federal health officials familiar with its production, and about 30 million doses by early April.

Mr. de Blasio also noted on Friday that the citywide seven-day average rate of positive test results was 8.63 percent, and city data show that in more than 30 city ZIP codes the rate is above 10 percent.

During the State of the City address, the mayor also said he would begin in May to bring back to offices the thousands of city employees who have been working remotely, and would safely reopen schools for all students in September.

“New York City’s vaccination effort is the foundation of a recovery for all of us,” the mayor’s 18-page recovery plan says. “With every vaccine shot, New York City moves closer and closer to fully reopening our economy, restoring the jobs we lost and ensuring equality in our comeback.”

If the federal government provides enough stimulus dollars to the city, Mr. de Blasio said, he will create a City Cleanup Corps of 10,000 temporary workers to focus on beautifying the city — an idea he compared to President Franklin D. Roosevelt’s Works Progress Administration during the Great Depression.

Mr. de Blasio also proposed two plans to help small businesses: a $50 million “recovery tax credit” program for businesses that have faced hardships from the pandemic, and a $100 million “recovery loan” program to help shops stay open. The city will provide low-interest loans of up to $100,000 to roughly 2,000 small businesses, according to the mayor’s plan.

But Mr. de Blasio has also warned that the city is facing major budget cuts and layoffs. He recently announced that the city’s property tax revenues are projected to decline by $2.5 billion next year, driven by a drop in the value of office buildings and hotel properties that have emptied out during the pandemic.

Gov. Andrew M. Cuomo announced on Friday that restaurants in New York City, major drivers of its economy that have struggled under pandemic restrictions, could reopen for indoor dining at 25 percent capacity starting on Feb. 14. Mr. Cuomo closed them last month as virus numbers ticked up.

Mr. de Blasio and Mr. Cuomo have expressed optimism that President Biden, along with a Democratic-led Congress, will bring substantial assistance to the city. Mr. de Blasio also called for higher taxes on wealthy New Yorkers in his speech — a policy he has pushed for years, but that Mr. Cuomo has opposed.

Mr. de Blasio noted that more than 100 billionaires in the state increased their net worth by billions of dollars during the pandemic and called again for a redistribution of wealth.

“There is clearly enough money in New York to invest in a fair and fast recovery — it’s just in the wrong hands,” he said.

A protest outside the Denver office of the Occupational Safety and Health Administration last year after hundreds of workers at a Colorado meatpacking plant developed Covid-19, six fatally.Credit…David Zalubowski/Associated Press

The federal occupational safety agency on Friday posted new guidance for employers on reducing the spread of Covid-19 in the workplace, just over one week after President Biden signed an executive order directing it to do so.

The move by the Occupational Safety and Health Administration, part of the Labor Department, includes only recommendations, not requirements. But the agency said it was exploring a rule mandating certain protective measures.

The agency declined to issue such a rule, known as an emergency temporary standard, during the Trump administration. But Mr. Biden indicated support for a standard during the campaign.

The new guidance makes fewer distinctions than the Trump administration’s version based on the exposure risk of different workers. “Everyone should be protected, not some more protected than others,” Ann Rosenthal, a senior adviser to the agency, said on a video call with reporters.

The document issued on Friday also uses less equivocal language than the agency did under President Donald J. Trump. For example, it says the most effective prevention programs “ensure that absence policies are nonpunitive.” During the Trump administration, the agency advised employers to “ensure that sick leave policies are flexible and consistent with public health guidance.”

Meatpacking and meat processing have been a particular source of concern, accounting for an outsized portion of Covid-19 infections nationally.

In late December, a state judge in California issued a temporary restraining order in a lawsuit involving workers at a local poultry plant, requiring a variety of safety protocols such as providing masks and requiring workers to wear them, as well as face shields, where social distancing isn’t possible.

The court announced Friday that it would issue a preliminary injunction to the same effect, giving workers an ongoing ability to force compliance if the company backs off the protocols. It cited evidence submitted by the plaintiffs that “regulatory agencies are overwhelmed by the issues raised by the Covid-19 pandemic and are unable to inspect with the same regularity as was the practice prior to the pandemic.”

Categories
Business

EU piles stress on AstraZeneca over delayed vaccines, reveals particulars of contract

The President of the European Commission, Ursula von der Leyen, will give a lecture at the end of a video conference of the members of the European Council that dealt with the Covid 19 pandemic in Brussels on January 21, 2021.

OLIVIER HOSLET | AFP | Getty Images

LONDON – The European Union released an edited version of the contract it signed with AstraZeneca on Friday as the bloc put pressure on the drug maker to deliver the promised Covid vaccine shipments.

The EU, which has been criticized for its slow adoption of vaccinations, was hit with a blow by AstraZeneca last week when the company said it could only deliver a fraction of the shots it agreed to for the first quarter.

AstraZeneca has denied it failed to deliver on its commitments, stating that shipments to the 27-nation bloc were targets rather than promises. The company also cited production problems at its European plants for the delays.

The European Commission, the EU executive, welcomed AstraZeneca’s commitment to greater transparency after the company agreed to publish details of the agreement. AstraZeneca was not immediately available to leave comments when CNBC contacted them.

The contract, which was signed on August 27, provides for AstraZeneca to undertake to the best of its ability to build capacity to produce 300 million doses of vaccine, with the Commission having the option to order an additional 100 million doses.

In the case of AstraZeneca, the agreement defines “best effort” as the activities a company with similar resources would undertake in the development and manufacture of its vaccine.

This includes “bearing in mind the urgent need for a vaccine to end a global pandemic that is creating serious public health problems, restrictions on personal freedoms and economic impacts around the world, but considering its effectiveness and safety”.

The contract states that AstraZeneca will use its “best possible efforts” to manufacture the vaccine at manufacturing facilities in the EU. The deal also provides for this to include plants based in the UK, although the country left the bloc last year.

AstraZeneca has been told to send some of the UK-made cans to the block, but the company said a separate deal with the UK prevented that.

The European Medicines Agency is expected to make a decision on Friday on whether the AstraZeneca vaccine will actually be approved for use.

International Competition Concerns

The President of the European Commission, Ursula von der Leyen, said on Friday morning on German radio: “There are binding orders and the contract is crystal clear.”

“AstraZeneca also explicitly assured us in this contract that no other obligations would prevent the fulfillment of the contract,” she said, according to Reuters.

Von der Leyen of the EU claimed the deal included clear delivery amounts for December and the first three quarters of 2021.

Earlier this week, Pascal Soriot, CEO of AstraZeneca, said the EU contract was based on what is known as a “best effort” clause and did not officially oblige the drug maker to a specific delivery schedule.

The EU von der Leyen rejected this proposal on Friday, adding that the clause would only apply if it was unclear whether AstraZeneca could develop a safe and effective vaccine. She also claimed that the contract specifically mentioned four manufacturing facilities that would supply the vaccine to Europe, two of which are in the UK.

A look at the headquarters of the British-Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca as a Covid-19 vaccine developed by AstraZeneca and inspected in Brussels, Belgium on January 28, 2021.

Dursun Aydemir | Anadolu Agency | Getty Images

EU officials have indicated that deliveries from the UK to Europe could be rerouted if delays in European production persist.

UK Prime Minister Boris Johnson said he remained “confident” of delivering the AstraZeneca vaccine developed in partnership with Oxford University. Johnson added that he was “very pleased” that the country was among the fastest in Europe to introduce the vaccine.

The UK has the second highest number of confirmed Covid cases in Europe after Russia, recording the highest number of coronavirus-related deaths of any European nation and the fifth highest worldwide.

The EU of around 450 million people is struggling to get its vaccinations up and running as it is insufficiently supplied and is currently lagging far behind countries like Israel and the UK in delivering vaccines to its citizens.

Vaccine maker Pfizer-BioNTech initially delivered a blow, announcing it would temporarily cut production to improve its production capacity in Belgium. This was followed by AstraZeneca last Friday, which reduced its delivery estimates for the region.

An unnamed senior EU official told Reuters that the bloc expected about 80 million doses by March but had been told it would only receive 31 million doses instead. The company has not confirmed the quantities concerned.

A deepening dispute between the EU and AstraZeneca has raised concerns about international competition for limited vaccine supplies. Hopefully the vaccinations can help end the coronavirus pandemic.

– CNBC’s Holly Ellyatt contributed to this report.

Categories
Health

EU suggests AstraZeneca diverts Covid-19 vaccines from UK

An AstraZeneca vaccine production line.

Bloomberg | Bloomberg | Getty Images

LONDON – The European Union has proposed that drug maker AstraZeneca reroute supplies of its coronavirus vaccine from the UK to mainland Europe as the battle over production delays and supplies continues.

It comes after AstraZeneca told the EU last week that it would initially deliver far fewer doses of its Covid vaccine to the block of 27 than initially thought.

The European Medicines Agency is expected to make a decision on Friday on whether the AstraZeneca vaccine will actually be approved for use.

In Germany, doubts have been expressed about the effectiveness of the vaccine in those over 65 years of age. On Thursday, the German vaccine committee recommended that the AstraZeneca vaccine only be offered to people between the ages of 18 and 64.

This is due to the fact that there is insufficient data to assess the effectiveness in people over 65 years of age.

Older study participants were later admitted to Phase 3 clinical trials of the AstraZeneca vaccine, which took place in the UK and Brazil, and earlier in South Africa. Therefore, there is less data on the effectiveness of the shot in those over 65.

Germany’s position casts doubt on the approval of the AstraZeneca vaccine at a time when a violent turmoil has broken out between the drug manufacturer and the EU over the delivery of the sting. The EU on Wednesday called for the pharmaceutical company to deliver on its agreement to supply millions of coronavirus vaccines by whatever means necessary.

“Constructive” discussions

Health Commissioner Stella Kyriakides said talks with the company, which continued on Wednesday, were “constructive”. But she also tweeted that “contractual obligations must be met, vaccines must be delivered to EU citizens”.

She said in a statement that the EU rejected the “first come, first served” logic after AstraZeneca’s CEO attributed delays in delivery to teething troubles at European manufacturing sites and ironing out similar issues in the UK. because they had ordered his vaccine dose three months earlier than the EU.

In a press conference, Kyriakides said there was “no hierarchy” in the manufacturing facilities identified in his pre-purchase agreement with AstraZeneca and no provision as to which EU would or would not supply.

“There are four factories in the contract, but there is no distinction between the UK and Europe. The UK factories are part of our pre-purchase agreement so they must deliver,” she said. There was no clause in the contract stating that the drug manufacturer would give priority to the UK, she added.

Slaughter brows

It is the latest development in the very public confrontation between the EU and AstraZeneca, as the latter is facing problems in two of their European plants.

The British-Swedish company’s CEO, Pascal Soriot, further fueled tensions on Tuesday when he said in an interview with the Italian newspaper La Repubblica that the deal with the EU was a “best possible” rather than a “contractual obligation”.

The EU hit back and asked the drug manufacturer to provide detailed plans for its delivery schedule. An official urged AstraZeneca to redirect cans made in the UK to the EU, despite the company’s failure to respond to the problem, according to a Reuters report.

In an interview on Tuesday, Soriot said: “The UK government said that delivery from the UK supply chain would go to the UK first. Basically it is. The EU agreement mentions that UK production facilities were an option for Europe, but later. “

UK Prime Minister Boris Johnson did not comment directly on the matter on Wednesday but said: “We are very confident in our deliveries, we are very confident in our contracts and we are proceeding on that basis.”

Vaccination drives

So far, the UK has vaccinated over 7.1 million people with a first dose of vaccine and nearly half a million received their second dose, which means more vaccinations have been received than Germany, France, Italy and Spain combined data numbers, according to Our World In.

Categories
Business

AstraZeneca CEO Pascal Soriot interview on provides to the EU

Pascal Soriot, managing director of AstraZeneca.

Simon Dawson | Bloomberg | Getty Images

Pascal Soriot, CEO of AstraZeneca, has defended the late launch of the coronavirus vaccine in the EU, saying the drug company is working “around the clock” to fix production problems. However, he also noted that the EU ordered three months later than the UK, which meant it was behind in addressing supply issues.

The EU has reacted angrily at a delay in AstraZeneca’s delivery of coronavirus vaccines to the bloc, which the European Medicines Agency is expected to approve later this week.

The 27-strong bloc expected around 80 million doses of the sting by the end of March, but will reportedly only receive around 31 million doses. With member states struggling to gain access to vaccines and rollout bursts, the EU has announced it will limit exports of EU-made Covid-19 vaccines.

Speaking to Italian newspaper La Repubblica, Soriot said delays in the delivery of his coronavirus vaccine were caused by a variety of production issues.

“We think we solved these issues, but we are basically two months behind where we wanted to be,” he said

The Anglo-Swedish drugmaker had also seen “such teething troubles in the British supply chain,” noted Soriot, but when the British deal was signed three months before the European vaccine deal, the company had “three additional months to fix any glitches that we have experienced. “

However, AstraZeneca continued to plan to deliver most of the vaccines promised to the EU in February. “But if we deliver what we want to deliver in February, it’s not a small volume. We are planning to deliver millions of cans to Europe, it’s not small,” he told the newspaper.

A Brazilian doctor will voluntarily receive an injection in July 2020 as part of phase 3 studies with a vaccine developed by Oxford University and the UK pharmaceutical company AstraZeneca.

Nelson Almeida | AFP | Getty Images

When asked what amount the EU could expect, Soriot said that once the vaccine is approved by the European Medicines Agency (EMA), “we will ship at least 3 million doses to Europe immediately, then we will have another shipment.” about a week later and then in the third or fourth week of February. The goal is to dispense 17 million cans by February. “

“It’s not as good as we’d like it to be, but it’s really not that bad,” he said. Globally, Soriot said production capacity would be 100 million cans as of February.

Anger in the EU

Talks between AstraZeneca and the EU took place on Monday. Afterward, EU Health Commissioner Stella Kyriakides said the discussions “have led to dissatisfaction with the lack of clarity and inadequate explanations”.

The EU has asked AstraZeneca to provide a detailed plan for vaccine delivery and timing of distribution. Further discussions are scheduled for Wednesday.

Some countries, including Italy, have threatened legal action against AstraZeneca for the delay. Others have asked why the UK, which relies heavily on the AstraZeneca surge to introduce vaccinations, has pushed ahead with its vaccination campaign and has not yet experienced supply shortages. It has immunized more than 6.8 million people with at least a first two-dose dose of the vaccine.

Soriot said the UK manufacturing facility was more productive and insisted that there was no anti-EU context.

“Firstly, we have different plants and they have different yields and different productivity. One of the highest yielding plants is in the UK because it started earlier. It also had its own problems, but we solved them all. Good productivity, but it’s the UK plant because it started earlier. “

“We don’t do it on purpose. I am European, I have Europe in my heart. Our chairman is Swede, is European. Our CFO is European. Many leaders are European. That is why we want to treat Europe as the best.” we can.”

He noted that the drug company had a “best effort” contract with the EU as it wanted to be delivered at the same time as the UK, even though it was later to request the vaccine. “By the way, we have not made a commitment to the EU. It is not an obligation that we have for Europe. It is a great effort.”

British Prime Minister Boris Johnson poses for a photo with a vial of the vaccine candidate Covid-19 from the University of AstraZeneca / Oxford.

WPA pool | Getty Images News | Getty Images

Scaling and production problems

With a coronavirus vaccine developed, clinically tested, and approved in less than a year, Soriot said it was natural for the scaling-up process to interfere.

“We’re scaling up to hundreds of millions, billions of doses of vaccines at a very fast rate. We didn’t have a vaccine a year ago. If you do that, you have glitches, you have scale-up problems.” He added that there were currently problems with the production of the vaccine substance in two European plants.

“For Europe, the active ingredient is essentially manufactured in two plants, one in the Netherlands and one in Belgium. The drug is actually manufactured in Italy and Germany. So from a drug point of view, we have full capacity. We have no problem.” The current problems have to do with the manufacture of the drug’s substance, “he said.

Categories
Health

AstraZeneca and Sinopharm clear regulatory hurdles in per week of vaccine milestones.

With the spread of the coronavirus vaccines developed by Moderna, as well as Pfizer and BioNTech, the world reached several more pandemic milestones this week. the advancement of attempts to examine other experimental recordings; and the approval or approval of coronavirus vaccines in several countries. The welcome news comes as the number of known infections climbs to 83 million worldwide.

  • The UK announced on Wednesday that it was the Oxford-AstraZeneca Vaccine. The vaccine is cheaper than others – $ 3-4 per dose – and unlike some of its freeze-bound counterparts, it can be kept in a regular refrigerator, making it easier to carry and administer. The vaccine should be given in two doses four weeks apart. However, the UK plans to wait up to 12 weeks for the second shot to release more doses for the first injections. Some early evidence suggests the delay might improve the vaccine’s ability to protect people from Covid-19, although experts have repeatedly suggested that more data is needed.

  • The state-owned Chinese company Sinopharm announced that one of its experimental vaccines, developed by the Beijing Institute of Biological Products, had an efficacy rate of 79 percent based on an interim analysis of the Phase 3 trials, prompting the Chinese government to give the shot full approval To give. The vaccine was also approved in the United Arab Emirates and Bahrain. The company has not yet released the detailed results of its late-stage clinical trials.

  • NovavaxThe Maryland-based company announced Monday the start of a late-stage clinical trial that will enroll approximately 30,000 people in the United States and Mexico. Two-thirds of the volunteers in the study will receive the company’s vaccine. The other 10,000 will receive a saline intake as a placebo. Like many other vaccines, Novavax’s vaccine requires two doses. The vaccine can be kept stable in a normal refrigerator.

  • The World Health Organization gave the Pfizer-BioNTech Vaccine Thursday an emergency seal of approval that was the first to be awarded to a Covid-19 vaccine. Adding it to the organization’s emergency list allows the vaccine to move faster through regulatory approval in countries around the world. The move also enables the vaccine to be distributed through Unicef ​​and the Pan American Health Organization.